All sponsors

CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS34
PHASE 3 / 2-315
RECRUITING9
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO0%

Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open CSPC Megalith Biopharmaceutical Co.,Ltd. on the live radar map → 📅 $1093.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SYS6010
NCT06927986
P3RecruitingEGFR-mutated Locally Advanced or Metastatic NSCLC3802026-07-30
SYS6010
NCT07256509
P2Not yet recruitingNon-Small Cell Lung Cancer1202026-11-30
SYNSTAR-02
NCT07376382
P3Not yet recruitingNSCLC6802026-12-12
A zoster mRNA vaccine SYS6017
NCT07354659
P2Not yet recruitingHerpes Zoster8002027-03-10
SYS6041
NCT07744763
P1/2RecruitingAdvanced Solid Tumors2602027-03-28
SYS6010 jnjection
NCT06775236
P1/2Not yet recruitingAdvanced Solid Tumors; Breast Cancer4102027-06-15
SYS6045
NCT07122063
P1/2Active, not recruitingAdvanced Solid Tumors2662027-07-30
Recombinant Zoster Vaccine (CHO cell) SYS6052
NCT07892989
P1/2Not yet recruitingHerpes Zoster4962027-07-31
SYS6010 injection
NCT07633873
P3Not yet recruitingNon-Small Cell Lung Cancer5002027-09-30
SYS6023
NCT07597629
P2RecruitingAdvanced Breast Cancer362027-11-30
SYS6043
NCT07415863
P1/2RecruitingAdvanced/Metastatic Solid Tumors8202027-12-30
JMT101
NCT06989671
P2Not yet recruitingHead and Neck Squamous Cell Carcinoma4302027-12-30 (+3 mo)
SYNSTAR03
NCT07442565
P3Not yet recruitingNon-Small Cell Lung Cancer5062027-12-30
SYS6090 (Fixed Dose Level A) + bevacizumab
NCT07750041
P1/2Not yet recruitingUnresectable Advanced or Metastatic Colorectal Cancer2602027-12-31
SYS6002
NCT07230626
P3Not yet recruitingCervical Cancer4122028-01-01
SYS6041, bevacizumab
NCT07714668
P2RecruitingOvarian Cancer; Recurrent Ovarian Cancer1712028-04-30
SYS6002
NCT07374549
P2Not yet recruitingAdvanced Urothelial Carcinoma1002028-06-01
SYS6010 injection
NCT07254585
P2RecruitingHead and Neck Squamous Cell Carcinoma1102028-06-30
SYS6010
NCT07758621
P3Not yet recruitingHead and Neck Squamous Cell Carcinoma3402028-09-15
SYS6026
NCT07702656
P2Not yet recruitingHigh-grade Cervical Intraepithelial Lesions1752028-09-30
SYS6043
NCT07833735
P1/2Not yet recruitingAdvanced Solid Tumors4002028-10-15
Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043
NCT07879911
P3Not yet recruitingTriple Negative Breast Cancer5502028-11-30
SYS6010
NCT07417735
P3Not yet recruitingLocally Advanced/Metastatic/Recurrent ESCC4362028-12-31
SYS6006
NCT07622225
P1/2Not yet recruitingAdvanced Solid Tumors2642028-12-31
SYS6088
NCT07857135
P1/2Not yet recruitingAdvanced/Metastatic Solid Tumors1402029-02-03
SYS6010
NCT07406542
P3Not yet recruitingRecurrent or Metastatic Breast Cancer4002029-04-01
SYS6062
NCT07897227
P1/2Not yet recruitingAdvanced Solid Tumors; Gastric Cancer (GC)2602029-05-01
SYS6002
NCT07526792
P3Not yet recruitingUrothelial Carcinoma4062029-06-01
SYS6090 Injection + Bevacizumab Injection
NCT07761286
P1/2Not yet recruitingHCC - Hepatocellular Carcinoma2882029-09-30
SYS6010
NCT07672223
P3RecruitingNon-small Cell Lung Cancer5862029-09-30
SYS6010 combined with Enlonstobart
NCT07925021
P3RecruitingPreviously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma4242029-10-01
SYS6043
NCT07708753
P3RecruitingPlatinum-resistant Ovarian Cancer; Platinum-resistant Primary Peritoneal Cancer4602029-10-01
SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)
NCT07251062
P2/3Not yet recruitingEsophageal Squamous Cell Carcinoma7372029-12-30
SYS6010
NCT07924111
P3Not yet recruitingEsophageal Squamous Cell Carcinoma5852029-12-30